Introducing SERB Pharmaceuticals

SERB Pharmaceuticals equips healthcare providers worldwide with lifesaving medicines for patients facing rare conditions and emergencies.

Healthcare providers in over 100 countries rely on us for a broad range of essential medicines delivered via healthcare systems, first responders, emergency preparedness agencies, and non-profit organisations.

Who we are

SERB began in the 1950s as Société d’Études et de Recherches Biologiques (Company for Biologic Study and Research).

For over 30 years we have consistently supplied emergency medicines, medical countermeasures, and the world’s leading portfolio of antidotes. In this time, we have built trusted partnerships, integrated infrastructure and quality processes to get our medicines to patients with urgency.

Our proven ability to acquire, develop, manufacture, launch and commercialize specialist medicines allows us to meet critical medical needs.

Improving patients’ quality of life and offering hope is what motivates and inspires us.

Learn more about SERB

80+

Medicines

500+

Dedicated employees

Direct sales in

18

countries

Supplying

100+

countries

Latest news

  • 13 January 2025
    Newly published study shows that Voraxaze® can improve clinical outcomes in patients with high-dose methotrexate induced acute kidney injury
    SERB Pharmaceuticals (SERB) announces the publication of the largest and most comprehensive study to date of patients with high-dose methotrexate (MTX)- induced acute kidney injury (MTX-AKI) treated with and without Voraxaze® (glucarpidase).
    Read release
  • 09 December 2024
    First FDA-approved treatment for severe frostbite now commercially available in the US 
    Philadelphia, 9 December 2024: SERB Pharmaceuticals, a global specialty pharmaceutical company, is proud to announce that Aurlumyn™ (iloprost) Injection, the first FDA-approved treatment for severe frostbite in adults to reduce the risk of digit amputations, is now commercially available in the US.1 Aurlumyn ™ is available through specialty distribution by FFF Enterprises Inc. Customers interested […]
    Read release
  • 21 October 2024
    SERB Pharmaceuticals expands leading emergency care portfolio with acquisition of Aurlumyn™ (iloprost IV) for severe frostbite
    Philadelphia, 21 October 2024: SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today the acquisition of Aurlumyn™ (iloprost IV), the only FDA approved treatment option for severe frostbite in the US, from CiVi Biopharma. Aurlumyn™ will be made available this coming winter season. Arthur Pignot, Chief Strategy Officer at SERB, said: “Aurlumyn™ is set to […]
    Read release
See all news

Latest insight

  • Diversity
  • Responsibility

Chris Sampson

11 February 2025

Encouraging women in STEM subjects

Today, on the International Day of Women and Girls in Science, we proudly celebrate the achievements and contributions of women in science, technology, and engineering around the globe.

Read more
See all insights
You are leaving the SERB.com global corporate website
This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. SERB declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, SERB is not responsible for any information or opinion contained in any third-party website.
Choose your region